Inicio>>Signaling Pathways>> GPCR/G protein>> CXCR>>PS372424

PS372424

Catalog No.GC37022

PS372424, un fragmento de tres aminoÁcidos de CXCL10, es un agonista de CXCR3 humano especÍfico con actividad antiinflamatoria.

Products are for research use only. Not for human use. We do not sell to patients.

PS372424 Chemical Structure

Cas No.: 914291-61-5

Tamaño Precio Disponibilidad Cantidad
5mg
232,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

PS372424, a three amino-acid fragment of CXCL10, is a specific human CXCR3 agonist with anti-inflammatory activity, which inhibits the binding of CXCR3 ligand CXCL10 to CXCR3 receptor with IC50 of 42 nM[1][2][3]. CXCR3

PS372424 (10-200 nM; 30 min) causes a concentration-dependent phosphorylation of CCR5 on CXCR3+ T cells not in CXCR3- T cells[1]. Western Blot Analysis[1] Cell Line: CXCR3+ T cells and CXCR3- T cells

[1]. BoyÉ K, et al. The role of CXCR3/LRP1 cross-talk in the invasion of primary brain tumors. Nat Commun. 2017 Nov 17;8(1):1571. [2]. O'Boyle G, et al. Chemokine receptor CXCR3 agonist prevents human T-cell migration in a humanized model of arthritic inflammation. Proc Natl Acad Sci U S A. 2012 Mar 20;109(12):4598-603. [3]. Stroke IL, et al. Identification of CXCR3 receptor agonists in combinatorial small-molecule libraries. Biochem Biophys Res Commun. 2006 Oct 13;349(1):221-8.

Reseñas

Review for PS372424

Average Rating: 5 ★★★★★ (Based on Reviews and 27 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for PS372424

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.